Erratum: Cognitive function and nigrostriatal markers in abstinent methamphetamine abusers (Psychopharmacology (2006) 185 (327-338) DOI: http//dx.doi.org/10.1007/s00213-006-0330-6);Cognitive function and nigrostriatal markers in abstinent methamphetamine abusers

Psychopharmacology

Volumn 185, Issue 3, 2006, Pages 327-338

  Johanson, Chris Ellyn ^a   Frey, Kirk A ^b,c   Lundahl, Leslie H ^a   Keenan, Pamela ^a   Lockhart, Nancy ^a   Roll, John ^d   Galloway, Gantt P ^e   Koeppe, Robert A ^b   Kilbourn, Michael R ^b   Robbins, Trevor ^f   Schuster, Charles R ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

^d FRIENDS RESEARCH INSTITUTE   (United States)

^e Haight Ashbury Free Clinics   (United States)

^f UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

DAT; Dopamine transporter; Human; Methamphetamine; Neurocognitive function; Neuroimaging; PET; VMAT2

Indexed keywords

ALCOHOL; CANNABIS; CENTRAL STIMULANT AGENT; COCAINE; DIHYDROTETRABENAZINE; DOPAMINE TRANSPORTER; METHAMPHETAMINE; METHYLPHENIDATE; OPIATE; SEDATIVE AGENT; VESICULAR MONOAMINE TRANSPORTER 2;

ABSTINENCE; ADULT; ARTICLE; ATTENTION; BRAIN FUNCTION; CLINICAL ARTICLE; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC IMAGING; DOPAMINERGIC NERVE CELL; DRUG ABUSE; DRUG MEGADOSE; FEMALE; HUMAN; LEARNING; LONG TERM EXPOSURE; MALE; MEMORY; MONOAMINE RELEASE; MOTOR ACTIVITY; MOTOR PERFORMANCE; NERVE ENDING; NIGRONEOSTRIATAL SYSTEM; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

EID: 33645105861     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-006-0393-4     Document Type: Erratum

References (46)

1. Ando K, Johanson CE, Schuster CR (1986) Effects of dopaminergic agents on eye tracking before and after repeated methamphetamine. Pharmacol Biochem Behav 24:693-699
2. Biederman J, Wilens T, Mick E, Milberger S, Spencer T, Faraone S (1995) Psychoactive substance use disorders in adults with attention deficit hyperactivity disorder (ADHD): effects of ADHD and psychiatric comorbidity. Am J Psychiatry 152:1652-1658
3. Bohnen NI, Albin RL, Koeppe RA, Wernette K, Kilbourn MR, Minoshima S, Frey KA (1996) Positron emission tomography of monoaminergic vesicular binding in aging and Parkinson disease. J Cereb Blood Flow Metab. DOI 10.1038/sj.jcbfm.9600276
4. Chang L, Ernst T, Speck O, Patel H, DeSilva M, Leonido-Yee M, Miller EN (2002) Perfusion MRI and computerized cognitive test abnormalities in abstinent methamphetamine users. Psychiatry Res 114:65-79
5. Delis D, Kramer J, Kaplan E, Ober B (1987) The California verbal learning test. Psychological Corporation
6. Ernst T, Chang L, Leonido-Yee M, Speck O (2000) Evidence for long-term neurotoxicity associated with methamphetamine abuse: a 1H MRS study. Neurology 54:1344-1349
7. First MB, Spitzer RL, Gibbon M, Williams JBW (1996) Structured clinical interview of DSM-IV axis I disorders - patient edition (SCID I/P), version 2. Biometrics Research Dept., NY State Psychiatric Institute
8. Frey K, Kilbourn M, Robinson T (1997) Reduced striatal vesicular monoamine transporters after neurotoxic but not after behaviorally-sensitizing doses of methamphetamine. Eur J Pharmacol 334:273-279
9. Harvey DC, Lacan G, Tanious SP, Melega WP (2000) Recovery from methamphetamine induced long-term nigrostriatal dopaminergic deficits without substantia nigra cell loss. Brain Res 871:259-270
10. Hotchkiss AJ, Gibb JW (1980) Long-term effects of multiple doses of methamphetamine on tryptophan hydroxylase and tyrosine hydroxylase activity in rat brain. J Pharmacol Exp Ther 214:257-262
11. Johanson CE, Aigner TG, Seiden LS, Schuster CR (1979) The effects of methamphetamine on fine motor control in rhesus monkeys. Pharmacol Biochem Behav 11:273-278
12. Kalechstein AD, Newton TF, Green M (2003) Methamphetamine dependence is associated with neurocognitive impairment in the initial phases of abstinence. J Neuropsychiatry Clin Neurosci 15:215-220
13. Klove J (1964) Clinical neuropsychology. Saunders, New York
14. 11C]dihydrotetrabenazine (DTBZ) and positron emission tomography. J Cereb Blood Flow Metab 17:919-931
15. 11C]dihydrotetrabenazine. J Cereb Blood Flow Metab 19:1376-1384
16. Lew R, Malberg J (1997) Evidence for and mechanism of action of neurotoxicity of amphetamine related compounds. In: Kostrzewa R (ed) Highly selective neurotoxins: basic and clinical applications. Humana, Totowa, NJ, pp 235-268
17. Lorez H (1981) Fluorescence histochemistry indicates damage of striatal dopamine nerve terminals in rats after multiple doses of methamphetamine. Life Sci 28:911-916
18. 11C]WIN-35,428. J Neurosci 18:8417-8422
19. Moszczynska A, Fitzmaurice P, Ang L, Kalasinsky KS, Schmunk GA, Peretti FJ, Aiken SS, Wickham DJ, Kish SJ (2004) Why is parkinsonism not a feature of human methamphetamine users? Brain 127:363-370
20. Nordahl TE, Salo R, Possin K, Gibson DR, Flynn N, Leamon M, Galloway GP, Pfefferbaum A, Spielman DM, Adalsteinsson E, Sullivan EV (2002) Low N-acetyl-aspartate and high choline in the anterior cingulum of recently abstinent methamphetamine-dependent subjects: a preliminary proton MRS study. Magnetic resonance spectroscopy. Psychiatry Res 116:43-52
21. Ornstein TJ, Iddon JL, Baldacchino AM, Sahakian BJ, London M, Everitt BJ, Robbins TW (2000) Profiles of cognitive dysfunction in chronic amphetamine and heroin abusers. Neuropsychopharmacology 23:113-126
22. Reitan R (1958) Validity of the trail making test as an indication of organic brain damage. Percept Mot Skills 8:271-276
23. Reitan R (1969) Manual for administration of neuropsychological test batteries for adults and children. Indianapolis
24. Ricaurte GA, Guillery RW, Seiden LS, Schuster CR, Moore RY (1982) Dopamine nerve terminal degeneration produced by high doses of methylamphetamine in the rat brain. Brain Res 235:93-103
25. Ringe W, Saine K, Lacritz L, Hynan L, Cullum C (2002) Dyadic short forms of the Wechsler intelligence scale III. Assessment 9:254-260
26. Robbins TW, James M, Owen AM, Sahakian BJ, McInnes L, Rabbitt P (1994) Cambridge neuropsychological test automated battery (CANTAB): a factor analytic study of a large sample of normal elderly volunteers. Dementia 5:266-281
27. Robbins TW, James M, Owen AM, Sahakian BJ, Lawrence AD, McInnes L, Rabbitt PM (1998) A study of performance on tests from the CANTAB battery sensitive to frontal lobe dysfunction in a large sample of normal volunteers: implications for theories of executive functioning and cognitive aging. Cambridge neuropsychological test automated battery. J Int Neuropsychol Soc 4:474-490
28. Salo R, Nordahl TE, Possin K, Leamon M, Gibson DR, Galloway GP, Flynn NM, Henik A, Pfefferbaum A, Sullivan EV (2002) Preliminary evidence of reduced cognitive inhibition in methamphetamine-dependent individuals. Psychiatry Res 111:65-74
29. Sattler J, Ryan J (2001) Tables for WAIS-III. In: Sattler J (ed) Assessment of children: cognitive applications. Jerome M. Sattle, San Diego, CA, pp 812-835
30. Seiden LS, Ricaurte G (1987) Neurotoxicity of methamphetamine and related drugs. In: Meltzer HY (ed) Psychopharmacology: the third generation of progress. Raven, New York, pp 359-366
31. Seiden LS, Fischman MW, Schuster CR (1976) Long-term methamphetamine induced changes in brain catecholamines in tolerant rhesus monkeys. Drug Alcohol Depend 1:215-219
32. Sekine Y, Iyo M, Ouchi Y, Matsunaga T, Tsukada H, Okada H, Yoshikawa E, Futatsubashi M, Takei N, Mori N (2001) Methamphetamine-related psychiatric symptoms and reduced brain dopamine transporters studied with PET. Am J Psychiatry 158:1206-1214
33. Sekine Y, Minabe Y, Ouchi Y, Takei N, Iyo M, Nakamura K, Suzuki K, Tsukada H, Okada H, Yoshikawa E, Futatsubashi M, Mori N (2003) Association of dopamine transporter loss in the orbitofrontal and dorsolateral prefrontal cortices with methamphetamine-related psychiatric symptoms. Am J Psychiatry 160:1699-1701
34. Simon SL, Domier C, Carnell J, Brethen P, Rawson R, Ling W (2000) Cognitive impairment in individuals currently using methamphetamine. Am J Addict 9:222-231
35. Simon SL, Domier CP, Sim T, Richardson K, Rawson RA, Ling W (2002) Cognitive performance of current methamphetamine and cocaine abusers. J Addict Dis 21:61-74
36. Sossi V, Holden J, Chan G, Krzywinski M, Stoessl A, Ruth T (2000) Analysis of four dopaminergic tracers kinetics using two different tissue input function methods. J Cereb Blood Flow Metab 20:653-660
37. Thompson PM, Hayashi KM, Simon SL, Geaga JA, Hong MS, Sui Y, Lee JY, Toga AW, Ling W, London ED (2004) Structural abnormalities in the brains of human subjects who use methamphetamine. J Neurosci 24:6028-6036
38. 3H]Methoxytetrabenazine: a high specific activity ligand for estimating monoaminergic neuronal integrity. Neuroscience 68:962-995
39. Vander Borght TM, Kilbourn MR, Desmond TJ, Kuhl DE, Frey KA (1995b) The vesicular monoamine transporter is not regulated by dopaminergic drug treatments. Eur J Pharmacol 294:577-583
40. Volkow ND, Ding YS, Fowler JS, Wang GJ, Logan J, Gatley SJ, Schlyer DJ, Pappas N (1995) A new PET ligand for the dopamine transporter: studies in the human brain. J Nucl Med 36:2162-2168
41. Volkow ND, Chang L, Wang GJ, Fowler JS, Franceschi D, Sedler M, Gatley SJ, Miller E, Hitzemann R, Ding YS, Logan J (2001a) Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence. J Neurosci 21:9414-9418
42. Volkow ND, Chang L, Wang GJ, Fowler JS, Leonido-Yee M, Franceschi D, Sedler MJ, Galley SJ, Hitzemann R, Ding YS, Logan J, Wong C, Miller EN (2001b) Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. Am J Psychiatry 158:377-382
43. Wagner GC, Ricaurte GA, Seiden LS, Schuster CR, Miller RJ, Westley J (1980) Long-lasting depletions of striatal dopamine and loss of dopamine uptake sites following repeated administration of methamphetamine. Brain Res 181:151-160
44. Wechsler D (1997) Wechsler adult intelligence scale - administration and scoring manual, 3rd edn. Psychological Corporation
45. Wilson JM, Kalasinsky KS, Levey AI, Bergeron C, Reiber G, Anthony RM, Schmunk GA, Shannak K, Haycock JW, Kish SJ (1996) Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. Nat Med 2:699-703
46. Zachary R (1986) Manual for the revised Shipley institute of living scale. Western Psychological Services